ZERO WORLD RESEARCHLiterature database on amino acids & organic acids

Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation.

Amino acids2015Pavlyk I, Rzhepetskyy Y, Jagielski AK, et al.
Study designOther primary literature
SubjectHuman

Record checks

Study design
Other primary literature
Subject
Human
Publication year
2015
Source
doi.org
Abstract display
Shown here
Publication status
Active
Status checked
17 Aug 2026
Collected
13 Aug 2026
Freshness
Current
Review stage
Automated
Record status
Published

Abstract

A deficit of exogenous arginine affects growth and viability of numerous cancer cells. Although arginine deprivation-based strategy is currently undergoing clinical trials, molecular mechanisms of tumor cells' response to arginine deprivation are not yet elucidated. We have examined effects of arginine starvation on cell motility, adhesion and invasiveness as well as on actin cytoskeleton organization of human glioblastoma cells. We observed for the first time that arginine, but not lysine, starvation affected cell morphology, significantly inhibited their motility and invasiveness, and impaired adhesion. No effects on glia cells were observed. Also, arginine deprivation in glioblastoma evoked specific changes in actin assembly, decreased β-actin filament content, and affected its N-terminal arginylation. We suggest that alterations in organization of β-actin resulted from a decrease of its arginylation could be responsible for the observed effects of arginine deprivation on cell invasiveness and migration. Our data indicate that arginine deprivation-based treatment strategies could inhibit, at least transiently, the invasion process of highly malignant brain tumors and may have a potential for combination therapy to extend overall patient survival.

MeSH

Actin CytoskeletonActinsArginineBrain NeoplasmsCell AdhesionCell Line, TumorCytoskeletonGlioblastomaHumansNeoplasm Invasiveness

DOI 10.1007/s00726-014-1857-1

PMID 25362567

View source →